Chad MBA - NLS Pharmaceutics Chief Officer
| NLSP Stock | USD 3.27 0.39 10.66% |
Insider
Chad MBA is Chief Officer of NLS Pharmaceutics AG
| Address | The Circle 6, Zurich, Switzerland, 8058 |
| Phone | 41 44 512 21 50 |
| Web | https://nlspharma.com |
NLS Pharmaceutics Management Efficiency
The company has return on total asset (ROA) of (2.2776) % which means that it has lost $2.2776 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.6292) %, meaning that it created substantial loss on money invested by shareholders. NLS Pharmaceutics' management efficiency ratios could be used to measure how well NLS Pharmaceutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NLS Pharmaceutics' Return On Capital Employed is relatively stable compared to the past year. As of 11/28/2024, Return On Equity is likely to grow to 1.45, while Return On Tangible Assets are likely to drop (6.92). At this time, NLS Pharmaceutics' Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 11/28/2024, Non Current Liabilities Total is likely to grow to about 3.4 M, while Total Current Liabilities is likely to drop slightly above 4.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 40 | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| Brian MD | Rezolute | 49 | |
| MBA MD | Eliem Therapeutics | 63 | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| Timothy Moore | Instil Bio | 63 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| Jeffrey Meckler | Indaptus Therapeutics | 57 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Sergio Quezada | Achilles Therapeutics PLC | 49 | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| Sandeep MD | Instil Bio | 55 | |
| Walt Esq | Indaptus Therapeutics | 63 | |
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Andrew Slee | Protagenic Therapeutics | 74 | |
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| William BASc | NervGen Pharma Corp | 60 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
Management Performance
| Return On Equity | -8.63 | ||||
| Return On Asset | -2.28 |
NLS Pharmaceutics Leadership Team
Elected by the shareholders, the NLS Pharmaceutics' board of directors comprises two types of representatives: NLS Pharmaceutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NLS. The board's role is to monitor NLS Pharmaceutics' management team and ensure that shareholders' interests are well served. NLS Pharmaceutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NLS Pharmaceutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sharon Keys, Head Affairs | ||
| iur LLM, G Counsel | ||
| Chad MBA, Chief Officer | ||
| Eric MD, CoFounder Officer | ||
| Elena ThyenPighin, Chief Officer | ||
| Alexander MBA, CEO President | ||
| George MD, Chief Development |
NLS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NLS Pharmaceutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.63 | ||||
| Return On Asset | -2.28 | ||||
| Current Valuation | 13.64 M | ||||
| Shares Outstanding | 3.82 M | ||||
| Shares Owned By Insiders | 40.85 % | ||||
| Shares Owned By Institutions | 19.40 % | ||||
| Number Of Shares Shorted | 55.99 K | ||||
| Price To Book | 4.84 X | ||||
| EBITDA | (11.8 M) | ||||
| Net Income | (12.17 M) |
Pair Trading with NLS Pharmaceutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.Moving together with NLS Stock
| 0.76 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.81 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.92 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against NLS Stock
| 0.86 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.77 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.6 | PHVS | Pharvaris BV | PairCorr |
| 0.5 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.48 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.
The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.